Cd38
Preclinical
Cd38 is one of 15 therapeutic programs targeting Kidney. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
19 competitors in Kidney
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbApproved
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 3
Fludara
SanofiPhase 1
Actemra
RochePreclinical
Imlifidase
HHansa Biopharma AB
Phase 2
Glypressin
MMallinckrodt
Preclinical
Imuran
LLegacy Health System
Preclinical
Glucagon
XXeris Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Cd38. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- Wwujianyong